105 related articles for article (PubMed ID: 19890063)
1. Comment on "Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression".
Sørensen RB; thor Straten P; Andersen MH
J Immunol; 2009 Nov; 183(10):6040. PubMed ID: 19890063
[No Abstract] [Full Text] [Related]
2. Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression.
Liu H; Liu L; Liu K; Bizargity P; Hancock WW; Visner GA
J Immunol; 2009 Jul; 183(2):1022-31. PubMed ID: 19564344
[TBL] [Abstract][Full Text] [Related]
3. Marrying immunotherapy with chemotherapy: why say IDO?
Muller AJ; Prendergast GC
Cancer Res; 2005 Sep; 65(18):8065-8. PubMed ID: 16166276
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy.
Yentz S; Smith D
BioDrugs; 2018 Aug; 32(4):311-317. PubMed ID: 29980987
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of indoleamine 2,3 dioxygenase activity by H2O2.
Poljak A; Grant R; Austin CJ; Jamie JF; Willows RD; Takikawa O; Littlejohn TK; Truscott RJ; Walker MJ; Sachdev P; Smythe GA
Arch Biochem Biophys; 2006 Jun; 450(1):9-19. PubMed ID: 16624246
[TBL] [Abstract][Full Text] [Related]
6. Evading immunity: new enzyme implicated in cancer.
Garber K
J Natl Cancer Inst; 2012 Mar; 104(5):349-52. PubMed ID: 22349199
[No Abstract] [Full Text] [Related]
7. 1-L-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-D-methyltryptophan.
Yuasa HJ; Ball HJ; Austin CJ; Hunt NH
Comp Biochem Physiol B Biochem Mol Biol; 2010 Sep; 157(1):10-5. PubMed ID: 20399882
[TBL] [Abstract][Full Text] [Related]
8. Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity.
Göbel C; Breitenbuecher F; Kalkavan H; Hähnel PS; Kasper S; Hoffarth S; Merches K; Schild H; Lang KS; Schuler M
Cell Death Dis; 2014 Dec; 5(12):e1568. PubMed ID: 25501829
[TBL] [Abstract][Full Text] [Related]
9. The role of tryptophan catabolism in acquisition and effector function of memory T cells.
Dai H; Dai Z
Curr Opin Organ Transplant; 2008 Feb; 13(1):31-5. PubMed ID: 18660704
[TBL] [Abstract][Full Text] [Related]
10. Effect of Indoleamine 2,3 Dioxygenase Inhibitor on the Cytotoxic Activity of Tumour-infiltrating Lymphocytes.
Le Naour S; Knol AC; Pandolfino MC; Khammari A; Dréno B
Acta Derm Venereol; 2019 Nov; 99(12):1186-1187. PubMed ID: 31408178
[No Abstract] [Full Text] [Related]
11. Antimicrobial and immunoregulatory properties of human tryptophan 2,3-dioxygenase.
Schmidt SK; Müller A; Heseler K; Woite C; Spekker K; MacKenzie CR; Däubener W
Eur J Immunol; 2009 Oct; 39(10):2755-64. PubMed ID: 19637229
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.
Yue EW; Douty B; Wayland B; Bower M; Liu X; Leffet L; Wang Q; Bowman KJ; Hansbury MJ; Liu C; Wei M; Li Y; Wynn R; Burn TC; Koblish HK; Fridman JS; Metcalf B; Scherle PA; Combs AP
J Med Chem; 2009 Dec; 52(23):7364-7. PubMed ID: 19507862
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
Selvan SR; Dowling JP; Kelly WK; Lin J
Curr Cancer Drug Targets; 2016; 16(9):755-764. PubMed ID: 26517538
[TBL] [Abstract][Full Text] [Related]
14. Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy.
Brochez L; Kruse V; Schadendorf D; Muller AJ; Prendergast GC
Front Immunol; 2021; 12():789473. PubMed ID: 34938297
[No Abstract] [Full Text] [Related]
15. Electric Pulse Responsive Magnetic Nanoclusters Loaded with Indoleamine 2,3-Dioxygenase Inhibitor for Synergistic Immuno-Ablation Cancer Therapy.
Yu B; Zhang W; Kwak K; Choi H; Kim DH
ACS Appl Mater Interfaces; 2020 Dec; 12(49):54415-54425. PubMed ID: 33237729
[TBL] [Abstract][Full Text] [Related]
16. Challenges in targeting the tryptophan metabolism in cancer immunotherapy.
Schollbach J; Löb S
Aging (Albany NY); 2021 Aug; 13(16):19952-19953. PubMed ID: 34446610
[No Abstract] [Full Text] [Related]
17. Mouse model for allogeneic immune reaction against fetus recapitulates human pre-eclampsia.
Nishizawa H; Hasegawa K; Suzuki M; Achiwa Y; Kato T; Saito K; Kurahashi H; Udagawa Y
J Obstet Gynaecol Res; 2008 Feb; 34(1):1-6. PubMed ID: 18226121
[TBL] [Abstract][Full Text] [Related]
18. IDO and outcomes in ovarian cancer.
Nelson BH
Gynecol Oncol; 2009 Nov; 115(2):179-80. PubMed ID: 19822256
[No Abstract] [Full Text] [Related]
19. Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua.
Brastianos HC; Vottero E; Patrick BO; Van Soest R; Matainaho T; Mauk AG; Andersen RJ
J Am Chem Soc; 2006 Dec; 128(50):16046-7. PubMed ID: 17165752
[TBL] [Abstract][Full Text] [Related]
20. Inhibitor of indoleamine-2,3-dioxygenase 1-methyl-D-tryptophan can stimulate the growth of immunogenic tumors.
Vasil'eva ED; Nikolin VP; Popova NA; Lushnikova EL; Kaledin VI
Bull Exp Biol Med; 2010 Oct; 149(5):625-7. PubMed ID: 21165403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
